Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Yi-Tian Qi, MM¹, Yi Hou, PhD², and Liang-Chen Qi, MD³

Abstract
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors still remains under investigation. Objective: The aim of this meta-analysis was to systematically assess the efficacy and safety profiles of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors. Methods: We performed a comprehensive search of several electronic databases up to September 2018 to identify clinical trials. The primary end point was overall survival, progression-free survival, disease controlled rate, objective response rate, and adverse events. Epidermal growth factor receptor-tyrosine kinase inhibitor emergent severe adverse events (grade ≥ 3) were analyzed. Odds ratio along with 95% confidence interval were utilized for main outcome analysis. Results: In total, we had 3 randomized controlled trials in this analysis. The group of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors had significantly improved progression-free survival (odds ratio = 0.34, 95% confidence interval = 0.29-0.40, P < .00001), as well as objective response rate (odds ratio = 10.48, 95% confidence interval = 3.87-28.34, P < .00001) and disease controlled rate (odds ratio = 6.03, 95% confidence interval = 4.41-8.25, P < .00001). However, there was no significant difference in overall survival with next-generation epidermal growth factor receptor-tyrosine kinase inhibitors (odds ratio = 1.05, 95% confidence interval = 0.85-1.31, P = .66). Meanwhile, the odds ratio for treatment-emergent severe adverse events (diarrhea, rash/acne, nausea, vomiting, anemia) between patients who received next-generation epidermal growth factor receptor-tyrosine kinase inhibitors and those who received first-generation epidermal growth factor receptor-tyrosine kinase inhibitors did not show safety benefit (P > .05). Conclusions: Next-generation epidermal growth factor kinase inhibitors were shown to be the better agent to achieve higher response rate and longer progression-free survival in patients with non-small cell lung cancer as the later-line therapy for previously treated patients with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors. Meanwhile, they did not achieve benefit in overall survival and safety compared with the chemotherapy group. Further research is needed to develop a database of all EGFR mutations and their individual impacts on the various treatments.

Keywords
NSCLC, EGFR-TKIs, pretreated patients, meta-analysis

Abbreviations
AE, adverse events; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitors; NCLC, non-small cell lung cancer; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RCTs, random control trials.

Received: January 10, 2019; Revised: September 20, 2019; Accepted: May 10, 2020.

1 Department of Radiology, China-Japan Union Hospital, Jilin University, Changchun, China
2 Department of Tissue Engineering, School of Pharmacy, Jilin University, Changchun, China
3 Department of Thoracic Surgery, China-Japan Union Hospital, Jilin University, Changchun, China

Corresponding Author:
Liang-Chen Qi, Department of Thoracic Surgery, China-Japan Union Hospital, Jilin University, No.126 Xiantai Street, Changchun, 130031, China.
Email: liangchen625@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
**Introduction**

Lung cancer remains the primary cause of cancer-related death in the world.\(^1\) Non-small cell lung cancer (NSCLC) comprises approximately 80\% to 85\% of all lung cancers. More than half of NSCLC cases are diagnosed at the advanced-stage with poor prognosis and are candidates for palliative adjuvant chemotherapy. Recent advances in genetic discoveries in NSCLC and the employment of specific inhibitors against them have played a key role in patients with disease at these stages.\(^2\)

Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletions (Ex19Del) and the exon 21 point mutation, L858R, are powerful predictive markers for response to EGFR tyrosine kinase inhibitors (TKIs) in advanced-stage NSCLC, which have been accepted as the standard of care in this setting.\(^3\)

As first-generation TKIs, gefitinib and erlotinib have consistently shown superior therapeutic efficacy and more favorable safety profiles than chemotherapy in patients who have a driver mutation in the EGFR gene for first-line therapy.\(^4-6\) However, some studies have reported that the presence of the T790M variant reduces binding of first-generation EGFR-TKIs to the ATP-binding pocket of EGFR, which have potentially led to disease progression.\(^7,8\)

Numerous genetic mutations have been identified as resistance mechanisms, and specific inhibitors are being developed against them. Next-generation TKIs, including second-generation TKIs (such as afatinib) and third-generation TKIs (osimertinib), have offered a potential alternative for patients who progressed after first-generation EGFR-TKI treatment.\(^2\)

Based on positive results from prospective trials in patients whose disease had progressed on first-generation EGFR-TKI, next-generation TKIs were used to maximize the effect on delaying disease progression. Today, the efficacy of next-generation EGFR-TKIs in patients with advanced NSCLC who failed first-generation EGFR-TKIs still remains to be fully investigated. We performed this meta-analysis by including relevant trials, which have been designed to determine the efficacy and toxicity of EGFR-TKIs and focus primarily on whether next-generation EGFR-TKIs were superior in patients with NSCLC previously treated with first-line EGFR-TKI therapy.

**Methods**

**Search Strategy**

We conducted a systematic screening process using PubMed, Embase, and Cochrane Database of Systematic Reviews from their inception to September 2018, based on the MeSH terms and free key words: “non small cell lung cancer” AND “EGFR-TKIs” AND “pretreated patients”. Literature was also searched using reference lists and materials.

**Study Selection Criteria**

Articles that were related to the following inclusion criteria were included in this analysis: (1) studies were designed as random control trials (RCTs), (2) trials focused on comparing next-generation EGFR-TKIs and chemotherapy, (3) patient with treatment-refractory advanced NSCLC after failure of first-generation EGFR-TKIs, (4) the outcomes were efficacy (overall survival [OS], progression-free survival [PFS], and tumor response) and toxicity (incidence of severe adverse effects), (5) full texts were available.

**Quality Assessment**

Two investigators separately assessed the quality of the retrieved studies. Study quality was evaluated using the Cochrane Collaboration’s “Risk of bias” tool.

**Data Extraction**

Two authors independently extracted the relevant data from each trial. Disagreement was settled through discussion. We extracted the main categories based on the following: first author’s family name, publication year, treatment regimen, number of patients, mean age, and end point of interests. We extracted the corresponding hazard ratios and risk ratios with 95\% confidence interval (95\%CI) to describe the end points of interest data.

**Statistical Analysis**

We performed the meta-analysis by pooling the results of OS, PFS, disease controlled rate (DCR), objective response rate (ORR), and adverse events (AEs). We utilized the Review Manager version 5.3 software (Revman; The Cochrane collaboration Oxford) to perform all statistical analyses. Chi-square test was used to assess the significance of heterogeneity, which was then examined through the I\(^2\) statistic.\(^9\) The fixed-effects model was used if the assessment of heterogeneity was insignificant (I\(^2\) ≤ 50\%). If the source of heterogeneity was not insignificant (I\(^2\) > 50\%), we used the random effects model for further analysis. A P value less than .05 was considered statistically significant.

**Results**

**Overview of Literature Search and Study Characteristics**

Totally, 376 articles were identified initially. During the preliminary screening of abstracts and titles, 8 publications were further included because of the exclusion criteria. At last, a final total of 3 RCTs\(^10-12\) were assessed for eligibility in the meta-analysis (Figure 1). All included studies in this study were based on high-quality evidence. Figure 2 shows the risk of bias summary; Table 1 provides a brief description of these 3 studies.

**Clinical and Methodological Heterogeneity**

Pooled analysis of PFS comparing next-generation EGFR-TKIs versus chemotherapy. In the analysis of the rate of PFS, all studies were
included, and the data are shown in Figure 3. The results showed that a significant difference in benefit was found between next-generation EGFR-TKIs and chemotherapy (odds ratio $= 0.34$, 95% CI $= 0.29$-$0.40$, $P < .00001$).

**Pooled analysis of OS comparing next-generation EGFR-TKIs versus chemotherapy.** Only 2 trials reported data on OS. As displayed in Figure 4, the pooled estimates of effect sizes showed no significant statistical difference in OS between the 2 groups (odds ratio $= 1.05$, 95% CI $= 0.85$-$1.31$, $P = .66$).

**Pooled analysis of ORR comparing next-generation EGFR-TKIs versus chemotherapy.** The random-effects model was used to pool the data on ORR since the heterogeneity across all studies was significantly high. The pooled data showed a significant difference in advantage between the 2 groups (odds ratio $= 10.48$, 95% CI $= 3.87$-$28.34$, $P < .00001$). In other words, next-generation EGFR-TKIs increased the ORR (Figure 5).

**Pooled analysis of AEs comparing next-generation EGFR-TKIs versus chemotherapy.** We defined grade 3/4 toxicities as severe AE. Data on diarrhea, rash/acne, nausea, vomiting, and anemia were included, and are shown in Figure 6. Meanwhile, all the above data did not reach a statistically significant level ($P > .05$).

**Pooled analysis of DCR comparing next-generation EGFR-TKIs versus chemotherapy.** The pooling DCR data did show advantage in the next-generation EGFR-TKIs group (odds ratio $= 6.03$, 95% CI $= 4.41$-$8.25$, $P < .00001$).

**Discussion**

Epidermal growth factor receptor tyrosine kinase inhibitors are accepted as first-line therapy in NSCLC harboring mutations in *EGFR*. Nonetheless, the majority of patients eventually progress. To our knowledge, acquiring resistance refers to disease progression after response to EGFR-TKI treatment. Nowadays, lacking effective treatment for patients with NSCLC with an activating *EGFR* mutation after development of acquired resistance to first-generation EGFR TKIs is a major clinical problem.

Researchers have focused on multiple resistance mechanisms for patients who acquired resistance to first-generation EGFR-TKIs. These mechanisms include secondary mutations of the driver oncogene, and the activation of new signaling pathways other than the EGFR pathway.

With resistance developed in patients who received previous first-generation EGFR TKIs, next-generation TKIs have drawn all the attention based on the positive results from previous trials in patients who have progressed after first-generation EGFR-TKI. Unlike reversible first-generation EGFR TKIs, second-generation TKIs (afatinib) is an irreversible ErbB-family blocker. Moreover, osimertinib, a third-generation, irreversible EGFR TKI inhibits primary EGFR-TKI sensitizing and secondary EGFR T790M resistance mutations.

The primary results of our study further supported the conclusion. Our analysis did not show difference between the groups in terms of OS, although the results of PFS and response rate were promising. In Miller’s study, since 39% patients were still alive, as the trial was post hoc analyzed in February 2012, no benefit was found in OS between the groups. Consistent with the similar results, statistical significance was not achieved in Nie’s study.

The effect on survival efficacy seemed to be associated with specific *EGFR* mutations, which might potentially separate patients into different biological categories. Patients treated by afatinib and osimertinib have different predictive and prognostic impacts with Del19 and L858R mutations in *EGFR*. A retrospective study reported that compared with the L858R-positive disease treated with osimertinib, the prevalence of secondary T790M mutation was associated with better response in del19-positive disease. In the future, studies comparing the...
next-generation EGFR-TKIs between patients with EGFR 19 del + T790M mutation and EGFR L858R + T790M mutation are needed.

The improved antitumor activity with second/third-generation TKIs noted in this study might reflect their more potent and irreversible inhibition of EGFR signaling. In addition, patients treated with second/third-generation TKIs had statistically significant improvement in the response rate in this study, which are consistent with previous trials.
Both treatments showed comparable AE profile, which will be useful in the consideration of second/third-generation TKIs for patients with EGFR mutation-positive NSCLC after first-line EGFR-TKI therapy. This finding suggests that the systematically established safety used in this trial worked well to keep patients on treatment, achieving the maximum benefit from next-generation TKIs. All AEs were manageable and predictable, and with low discontinuation rates, indicating that proactive supportive therapy and dose modification were an adequate strategy to select EGFR inhibition.

In this systematic analysis assessing effect of next-generation TKIs in patients with advanced NSCLC after failure on first-generation EGFR-TKIs, there are some limitations that should not be ignored. First, the current study on the rate of OS provided insufficient data. Thus, there was no strong statistical evidence to be analyzed; Secondly, as this study was a study-level meta-analysis, imbalance existed between the 2 groups due to different qualities and different uses of EGFR-TKIs of the included studies, and the findings of the current study might be affected by clinical heterogeneity among the trials; Thirdly,
subgroup analysis of EGFR mutations in the 2 cohorts did not provide enough data on subtype, so we could not extract subgroup data from the literature.

Conclusion

Acquired resistance refers to disease progression after response to first-generation EGFR-TK; the survival outcome is dismal if resistance occurs. Our data showed that next-generation EGFR-TKI could prolong PFS and improve the response rate in patients with NSCLC who failed first-generation EGFR-TKI.

Relevant clinical studies have been conducted to develop the paradigm of “personalized” medicine in the treatment of NSCLC, at least in an oncogene-driven subset of patients; examples include mutations in the EGFR gene. From an efficacy standpoint, further trials on biomarkers that will benefit patients by molecular stratification, which can be instructive in guiding treatment decisions, with manageable AEs. It is important to consider the risk of AEs when choosing treatment, particularly in patients with underlying immune dysfunction.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Liang-Chen Qi  https://orcid.org/0000-0001-5111-9229

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Kazaz SN, Oztop I. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Turk Thorac J. 2017;18(3):66-71.
3. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015;33(30):3488-3515.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med. 2010;362(25):2380-2388.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
7. Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010;70(3):868-874.
8. Cross DA, Ashton SE, Ghiorgiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
10. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-538.
11. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Eng J Med. 2017;376(7):629-640.
12. Nie K, Zhang Z, Zhang C, et al. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018;121:5-11.
13. Yu Z, Boggot TJ, Kobayashi S, et al. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007;67(21):10417-10427.
14. Kobayashi S, Ji H, Yuzo Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005;65(16):7096-7101.
15. Romanidou O, Landi L, Cappuzzo F, Caliﬁano R. Overcoming resistance to first/second generation epidermal growth factor
receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. *Ther Adv Med Oncol.* 2016;8(3):176-187.

16. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol.* 2010;28(2):357-360.

17. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer.* 2010;10(11):760-774.

18. Heigener DF, Reck M. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: impact on treatment beyond gefitinib and erlotinib. *Adv Therapy.* 2011;28(2):126-133.

19. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018;378(2):113-125.

20. Zhou C, Yao LD. Strategies to improve outcomes of patients with EGFR-mutant non-small cell lung cancer: review of the literature. *J Thorac Oncol.* 2016;11(2):174-186.

21. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene.* 2008;27(34):4702-4711.

22. Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. *Ann Oncol.* 2018;29(3):687-693.

23. Davies RS, Nelmes DJ, Butler R, Lester JF. Non-small cell lung cancer in South Wales: are exon 19 deletions and L858R different? *Anticancer Res.* 2016;36(8):4267-4271.

24. Koyama N, Watanabe Y, Iwai Y, et al. Distinct benefit of overall survival between patients with non-small-cell lung cancer harboring EGFR exon 19 deletion and exon 21 L858R substitution. *Chemotherapy.* 2017;62(3):151-158.

25. Ke EE, Zhou Q, Zhang QY, et al. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. *J Thorac Oncol.* 2017;12(9):1368-1375.

26. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. *J Pharmacol Exp Ther.* 2012;343(2):342-350.